IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation

Hepatocellular Carcinoma Clinical Trial

— iPLENTY-pvtt  

Official title:

PILOT Study on the Safety and Efficacy of IMRT Combined With PD-1 Blockade and LEnvatinib as Neoadjuvant TherapY for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus (Vp3) Before Liver Transplantation（iPLENTY-pvtt）

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05339581
• Other study ID #: Renji-IIT2022-011
• Status: Not yet recruiting
• Phase: N/A
• Start date: May 20, 2022
• Est. completion date: May 31, 2024

Study information

• Verified date: April 2022
• Source: RenJi Hospital
• Contact: Hao Feng, MD, Ph.D
• Phone: 008615000901110
• Email: surgeonfeng[@]live.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a parallel assigned, open-label, perspective trial studying the safety and efficacy of intensity-modulated radiotherapy (IMRT) combined with PD-1 Blockade and Lenvatinib for Hepatocellular Carcinoma (HCC) with Vp3 Portal Vein Tumor Thrombus (PVTT, Japanese Liver Cancer Study Group classification) before liver transplantation.

Description:

In most criteria (e.g.Milan, UCSF, Up-to-seven), PVTT remains as an absolute contraindication for liver transplant due to the high rate of recurrence and poor prognosis. Neoadjuvant therapy has induced pathological responses in multiple tumor types and might decrease the risk of postoperative recurrence in HCC. The primary endpoint is the necrosis rate of PVTT and the primary tumor. Participants receive PD-1 Blockade (Pembrolizumab，Sintilimab， Camrelizumab，Tislelizumab) 200 mg intravenously on day 1 of a regular treatment cycle and Lenvatinib Mesylate Capsule (Lenvima®) 8 mg orally once daily. Neoadjuvant IMRT will be initiated at the third treatment cycle, and the dose prescription of IMRT is for planning target volume (PTV). The prescription dose to 95%PTV should be ≥50 Gy and ≤60 Gy, and been given in daily dose fractions of 2 Gy, 5 days per week. And the final prescription dose is determined according to dose constraints for organs at risk.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 78
• Est. completion date: May 31, 2024
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients must have pathologically or cytologically or by radiological criteria proven hepatocellular carcinoma(exceeding Milan criteria); known mixed histology (e.g. hepatocellular carcinoma plus cholangiocarcinoma) or fibrolamellar variant is not allowed.
• The maximum diameter of a single tumor =9cm. Or the number of tumors =3 and the maximum diameter of the largest tumors =5cm, and the sum of the maximum diameters of all tumors =9cm.
• Vp3 PVTT according to Japanese Vp classification.
• Without lymph node metastasis or extrahepatic metastasis.
• Baseline AFP=20ng/ mL
• Has an eligibility scan (CT of the chest, triphasic CT scan and MRI of the abdomen) <1 week before the treatment.
• Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days prior to Cycle 1, Day 1.
• Has a Child-Pugh A-B7 liver score (5 to 7 points) within 7 days prior to Cycle 1, Day 1.
• Laboratory tests within 7 days prior to Cycle 1, Day 1:
• Neutrophils =1.5×109/L
• Hemoglobin =8.5g/dL
• Platelets =100×109/L,
• Creatinine =1.5× upper limit of normal (ULN) and endogenous creatinine clearance =50ml/min (standard Cockcroft Gaul formula)
• Total bilirubin =3×ULN, ALT=5×ULN, AST=5×ULN, INR=1.7
• Has controlled hepatitis B (HBV-DNA<105IU/ml)
• The estimate time length between enrollment and liver transplantation should be at least 3 months.
• No prior systematic therapy such as immunotherapy, targeted therapy and chemotherapy for HCC.
• No prior local treatment such as TACE, HAIC, radiofrequency ablation or radiotherapy was received within 2 months before enrollment.
• If female, is not pregnant or breastfeeding, and at least one of the following conditions applies: 1) Is not a woman of childbearing potential (WOCBP); or 2) Is a WOCBP and using a contraceptive method that is highly effective or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (a WOCBP must have a negative pregnancy test within 72 hours before the first dose of study treatment).
• No obvious insufficiency of other organs.
• Patients with a history of hypertension should be well controlled (< 140/90 mmHg) on a regimen of anti-hypertensive therapy.
• Patients voluntarily joined the study and signed informed consent with good compliance and follow-up.

Exclusion Criteria:

• • Known mixed histology (e.g. hepatocellular carcinoma plus cholangiocarcinoma) or fibrolamellar variant.
• Surgery within the past 6 months.
• Has had esophageal or gastric variceal bleeding within the last 6 months.
• Has clinically apparent ascites on physical examination.
• Has received systematic therapy such as immunotherapy, targeted therapy and chemotherapy for HCC.
• Has received TACE, HAIC, radiofrequency ablation and other local treatments in recent 2 months.
• Has received liver radiotherapy.
• Has received radiotherapy with grade 4 toxicity.
• Significant history of cardiac disease is not allowed: Congestive heart failure > class II New York Heart Association (NYHA) Myocardial infarction within 6 months prior to registration Serious myocardial dysfunction, defined as scintigraphically (multigated acquisition scan [MUGA], myocardial scintigram) determined absolute left ventricular ejection fraction (LVEF) below 45% or an LVEF on echocardiogram (ECHO) below the normal limit at the individual institution.
• Has severe hypersensitivity (=Grade 3) to monoclonal antibody.
• Has an active autoimmune disease that has required systemic treatment (skin diseases that do not require systemic treatment such as vitiligo, psoriasis; type I diabetes, and autoimmune hypothyroidism due to hormone replacement therapy are allowed).
• Patients with other active malignant tumors within 5 years before the first use of the study drug (cured localized tumors such as basal cell carcinoma of skin, squamous cell carcinoma of skin, superficial bladder cancer, carcinoma in situ of prostate, carcinoma in situ of cervix and carcinoma in situ of breast are allowed).
• Has an active infection requiring systemic therapy.
• Has a known history of human immunodeficiency virus (HIV) infection.
• Has known active tuberculosis within 5 years.
• Has received a live vaccine within 30 days prior to the first dose of study treatment.
• Has received bone-marrow allotransplantation or solid organ transplantation.
• Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to Cycle 1, Day 1.
• Dysphagia or known drug absorption disorder.
• Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment.
• Conditions considered unsuitable for inclusion by other researchers.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Hepatocellular Carcinoma
• Liver Cancer
• Liver Transplant; Complications
• Portal Vein Thrombosis
• Radiotherapy; Complications
• Thrombosis

Intervention

Radiation:
• intensity-modulated radiotherapy
Neoadjuvant IMRT will be initiated at the third treatment cycle, and the dose prescription of IMRT is for planning target volume (PTV). The prescription dose to 95%PTV should be =50 Gy and =60 Gy, and been given in daily dose fractions of 2 Gy, 5 days per week. And the final prescription dose is determined according to dose constraints for organs at risk.

Combination Product:
• Pembrolizumab
Participants receive PD-1 Blockade (Pembrolizumab 200mg,Sintilimab 200mg, Camrelizumab 200mg,Tislelizumab 200mg) 100-200 mg intravenously on day 1 of a regular treatment cycle until >42 days before liver transplantation or unacceptable toxicity develops. Participants receive Lenvatinib Mesylate Capsule (Lenvima®) 8 mg orally once daily until >7 days before liver transplantation.

Drug:
• Sintilimab
Sintilimab is a recombinant anti-human PD-1 monoclonal antibody.
• Camrelizumab
Camrelizumab is a humanized anti-human PD-1 monoclonal antibody.
• Tislelizumab
Tislelizumab is a recombinant anti-human PD-1 monoclonal antibody.
• Lenvatinib Mesylate Capsule
Lenvatinib (Lenvima®, Eisai China) is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor ß, RET and KIT.

Locations

Country	Name	City	State
China	Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
RenJi Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PVTT RR/NR	Portal vein tumor thrombus related Response and Necrosis Rate	up to 12 months
Secondary	Alpha Fetoprotein Response (AFP-R)	AFP-R is defined as a >20% decrease in AFP serum level from baseline to the time of liver transplant, if liver transplant is not possible, the final AFP level would be measured as the AFP level at 12 months.	up to 12 months
Secondary	Progression-free survival (PFS)	PFS is defined as the time from the date of treatment initiation to the date of the first observation of progressive disease (PD) by independent radiologic review according to mRECIST criteria or death from any cause.	up to 12 months
Secondary	Objective Response Rate (ORR)	RR is defined as the proportion of patients whose tumor volume has reached a predetermined value and can maintain a minimum time limit, including complete response(CR) and partial response(PR) by independent radiologic review according to mRECIST criteria.	up to 12 months
Secondary	Time to Progression (TTP)	TTP is defined as the duration from the date of patient recruited to the first progress at any site or the date of death from any cause.	up to 12 months
Secondary	Duration of response (DOR)	DOR is defined as the duration from the date that measurement criteria are met for CR or PR to the first progress at any site or the date of death from any cause.	up to 12 months